BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 24, 2003
 |  BioCentury  |  Strategy

Compugen: Dry + wet goes downstream

Compugen Ltd. began life as a bioinformatics play, but it has always believed that bioinformatics companies must prove the predictive power of their software by performing their own wet lab experiments. The company is now using the discoveries from its technology to gradually turn itself from a pure service provider into a discovery company.

In the first such deal, CGEN (Tel Aviv, Israel) granted Diagnostic Products Corp. (DP, Los Angeles, Calif.) exclusive rights to develop and market cancer immunodiagnostics based on two prostate-specific RNA splice variants discovered by CGEN: PSA-linked molecule (PSA-LM) and hK2-linked molecule (K-LM) (see BioCentury, Jan. 27).

For CEO Mor Amitai, the deal is the first of more to come. "It is now a gradual shift...

Read the full 579 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >